1
|
Hamilton E, Oliveira M, Turner N, García-Corbacho J, Hernando C, Ciruelos EM, Kabos P, Borrego MR, Armstrong A, Patel MR, Vaklavas C, Twelves C, Boni V, Incorvati J, Brier T, Gibbons L, Klinowska T, Lindemann JPO, Morrow CJ, Sykes A, Baird R. A Phase 1 dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results. Ann Oncol 2024:S0923-7534(24)00138-8. [PMID: 38729567 DOI: 10.1016/j.annonc.2024.04.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2024] [Revised: 04/26/2024] [Accepted: 04/29/2024] [Indexed: 05/12/2024] Open
Abstract
BACKGROUND SERENA-1 (NCT03616587) is a Phase 1, multi-part, open-label study of camizestrant in pre- and post-menopausal women with ER+, HER2- advanced breast cancer. Parts A and B aim to determine the safety and tolerability of camizestrant monotherapy and define doses for clinical evaluation. Patients and Methods Women aged 18 years or older with metastatic or recurrent ER+, HER2- breast cancer, refractory (or intolerant) to therapy were assigned 25 mg up to 450 mg once daily (QD; escalation) or 75, 150, or 300 mg QD (expansion). Safety and tolerability, anti-tumor efficacy, pharmacokinetics, and impact on ESR1m circulating tumor (ct)DNA levels were assessed. RESULTS By 9 March 2021, 108 patients received camizestrant monotherapy at 25-450 mg doses. Of these, 93 (86.1%) experienced treatment-related adverse events (TRAEs), 82.4% of which were grade 1 or 2. The most common TRAEs were visual effects (56%), (sinus) bradycardia (44%), fatigue (26%), and nausea (15%). There were no TRAEs grade 3 or higher, or treatment-related serious adverse events (TRSAEs) at doses ≤150 mg. Median tmax was achieved ∼2-4 hours post-dose at all doses investigated, with an estimated half-life of 20-23 hours. Efficacy was observed at all doses investigated, including in patients with prior CDK4/6 inhibitor and/or fulvestrant treatment, with and without baseline ESR1 mutations, and with visceral disease, including liver metastases. CONCLUSIONS Camizestrant is a next-generation oral SERD and pure ER antagonist with a tolerable safety profile. The pharmacokinetics profile supports once-daily dosing, with evidence of pharmacodynamic and clinical efficacy in heavily pre-treated patients, regardless of ESR1m. This study established 75, 150 and 300 mg QD doses for Phase 2 testing (SERENA-2, NCT04214288 and SERENA-3, NCT04588298).
Collapse
Affiliation(s)
- E Hamilton
- Sarah Cannon Research Institute, Nashville, TN, USA
| | - M Oliveira
- Medical Oncology Department, Vall d'Hebron University Hospital and Breast Cancer Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - N Turner
- Breast Cancer Now, Toby Robins Research Centre, Institute of Cancer Research, London, UK
| | | | - C Hernando
- Department of Medical Oncology, Hospital Clinico Universitario de Valencia, Biomedical Research Institute (INCLIVA), Valencia, Spain
| | - E M Ciruelos
- Medical Oncology Department, 12 de Octubre University Hospital, Madrid, Spain
| | - P Kabos
- Division of Medical Oncology, University of Colorado, CO, USA
| | - M R Borrego
- Department of Medical Oncology, H U Virgen del Rocio, Seville, Spain
| | - A Armstrong
- The Christie NHS Foundation Trust and the University of Manchester, Manchester, UK
| | - M R Patel
- Florida Cancer Specialists/Sarah Cannon Research Institute/Sarasota Memorial Hospital, Sarasota, FL, USA
| | - C Vaklavas
- Huntsman Cancer Institute, University of Utah, UT, USA
| | - C Twelves
- Leeds Teaching Hospitals NHS Trust and University of Leeds, Leeds, UK
| | - V Boni
- START Madrid, CIOCC, Madrid, Spain
| | - J Incorvati
- Fox Chase Cancer Center, East Norriton-Hospital Outpatient Center, Philadelphia, PA, USA
| | - T Brier
- Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK
| | - L Gibbons
- Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK
| | - T Klinowska
- Late Development, Oncology R&D, AstraZeneca, Cambridge, UK
| | - J P O Lindemann
- Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK
| | - C J Morrow
- Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK
| | - A Sykes
- Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK
| | - R Baird
- Cancer Research UK, Cambridge Centre, Cambridge, UK.
| |
Collapse
|
2
|
Madrigal J, Martín A, Chambel R, Guijarro M, Hernando C, Callejas M, Espinosa J, Climent J. Do cone age and heating mode determine the opening of serotinous cones during wildfires? A new bench scale approach applied to Pinus halepensis Mill. Sci Total Environ 2021; 763:144222. [PMID: 33383513 DOI: 10.1016/j.scitotenv.2020.144222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/18/2020] [Revised: 11/25/2020] [Accepted: 11/25/2020] [Indexed: 06/12/2023]
Abstract
Serotiny is a well-known fire adaptive trait in some species, as the Mediterranean conifer Pinus halepensis. However, information about cone opening mechanisms during wildfires and consequences on post fire dispersal is scarce. In addition, standardized methods allowing a realistic simulation of heating modes at bench-scale are not available. In this study, we address for the first time the interacting effects of radiation, convection and direct flame on the opening and seed release of serotinous cones, following a novel repeatable methodology. Using a Mass Loss Calorimeter (MLC) device and a wide range of heat exposures (between 5 and 75 kW m-2) with or without ignition, we intended to simulate realistic cone heating during surface and crown fires in laboratory conditions. Additionally, we included the effect of contrasting serotinous cone ages interacting with heating mode and considering the random individual variation. The proposed methodology has shown a high potential to simulate the complex process of crown fires in relation to cone opening under controlled conditions, detecting a threshold of heat exposure (25-30 kW m-2) for cone opening. We confirmed that heating mode had a highly significant effect in cone opening, interacting with cone age, while cone age effect on its own was marginal. Particularly, ignition significantly increased the efficacy of cone opening and seed release. Moreover, young and old cones behave differently in seed release, both in surface and crown fire simulations. Implementing and adjusting this methodology in other species will allow more realistic and reliable quantitative comparisons than previously attained.
Collapse
Affiliation(s)
- J Madrigal
- INIA, Forest Research Centre, Department of Forest Dynamics and Management, Forest Fire Laboratory, Ctra. Coruña Km 7,5, 28040 Madrid, Spain; iuFOR, University Institute for Sustainable Forest Management, UVA-INIA, Spain; ETSI Montes, Forestal y del Medio Natural, University Politechnic of Madrid (UPM), Ramiro de Maeztu s/n, 28040 Madrid, Spain.
| | - A Martín
- ETSI Montes, Forestal y del Medio Natural, University Politechnic of Madrid (UPM), Ramiro de Maeztu s/n, 28040 Madrid, Spain
| | - R Chambel
- INIA, Forest Research Centre, Department of Forest Ecology and Genetics, Genetics Laboratory, Ctra. Coruña Km 7,5, 28040 Madrid, Spain
| | - M Guijarro
- INIA, Forest Research Centre, Department of Forest Dynamics and Management, Forest Fire Laboratory, Ctra. Coruña Km 7,5, 28040 Madrid, Spain; iuFOR, University Institute for Sustainable Forest Management, UVA-INIA, Spain
| | - C Hernando
- INIA, Forest Research Centre, Department of Forest Dynamics and Management, Forest Fire Laboratory, Ctra. Coruña Km 7,5, 28040 Madrid, Spain; iuFOR, University Institute for Sustainable Forest Management, UVA-INIA, Spain
| | - M Callejas
- INIA, Forest Research Centre, Department of Forest Ecology and Genetics, Genetics Laboratory, Ctra. Coruña Km 7,5, 28040 Madrid, Spain
| | - J Espinosa
- INIA, Forest Research Centre, Department of Forest Dynamics and Management, Forest Fire Laboratory, Ctra. Coruña Km 7,5, 28040 Madrid, Spain; iuFOR, University Institute for Sustainable Forest Management, UVA-INIA, Spain
| | - J Climent
- iuFOR, University Institute for Sustainable Forest Management, UVA-INIA, Spain; INIA, Forest Research Centre, Department of Forest Ecology and Genetics, Genetics Laboratory, Ctra. Coruña Km 7,5, 28040 Madrid, Spain
| |
Collapse
|
3
|
Martínez-Navarro I, Montoya-Vieco A, Hernando C, Hernando B, Panizo N, Collado E. The week after running a marathon: Effects of running vs elliptical training vs resting on neuromuscular performance and muscle damage recovery. Eur J Sport Sci 2021; 21:1668-1674. [PMID: 33251988 DOI: 10.1080/17461391.2020.1857441] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Our aim was to compare the effects of two exercise modalities vs resting on the time course of neuromuscular performance and muscle damage recovery during the week after running a marathon. Sixty-four finishers from a road marathon completed the study (54 men and 10 women; 39 ± 4 years; 3 h 35 min ± 21 min). The day before the race, within 15 min after finishing the marathon and at 24, 48, 96, 144 and 192 h postrace, lactate dehydrogenase and creatine kinase were analysed. Participants also performed a squat jump (SJ) test before and after the marathon and at 48, 96 and 144 h postrace. On their arrival to the finish line, participants were randomized into one of the three intervention groups: running (RUN), elliptical training (ELIP) and resting recovery (REST). RUN and ELIP groups exercised continuously for 40 min at a moderate intensity (95-105% of the HR corresponding to the first ventilatory threshold) at 48, 96 and 144 h after the marathon. Neither 'Intervention' factor nor 'Intervention x Time' interaction effects were revealed for muscle damage blood markers (p > 0.05). On the other hand, RUN group evidenced an enhancement in SJ performance 96 h post-marathon as compared with REST group (108.29 ± 10.64 vs 100.58 ± 9.16%, p = 0.020, d = 0.80). Consequently, return to running at 48 h post-marathon does not seem to have a negative impact on muscle damage recovery up to eight days post-race and it could be recommended in order to speed up neuromuscular recovery.
Collapse
Affiliation(s)
- I Martínez-Navarro
- Physical Education and Sports Department, University of Valencia, Valencia, Spain.,Sports Health Unit, Vithas 9 de Octubre Hospital, Valencia, Spain
| | - A Montoya-Vieco
- Physical Education and Sports Department, University of Valencia, Valencia, Spain.,Sports Health Unit, Vithas 9 de Octubre Hospital, Valencia, Spain
| | - C Hernando
- Sport Service, Jaume I University, Castellon, Spain.,Department of Education and Specific Didactics, Jaume I University, Castellon, Spain
| | - B Hernando
- Department of Medicine, Jaume I University, Castellon, Spain
| | - N Panizo
- Department of Medicine, Jaume I University, Castellon, Spain.,Universitary Clinical Hospital of Valencia, Valencia, Spain
| | - E Collado
- Faculty of Health Sciences, Jaume I University, Castellon, Spain
| |
Collapse
|
4
|
Martínez-Navarro I, Sánchez-Gómez J, Sanmiguel D, Collado E, Hernando B, Panizo N, Hernando C. Immediate and 24-h post-marathon cardiac troponin T is associated with relative exercise intensity. Eur J Appl Physiol 2020; 120:1723-1731. [PMID: 32468283 DOI: 10.1007/s00421-020-04403-8] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2020] [Accepted: 05/19/2020] [Indexed: 10/24/2022]
Abstract
PURPOSE We aimed at exploring whether cardiopulmonary fitness, echocardiographic measures and relative exercise intensity were associated with high-sensitivity cardiac troponin T (hs-TNT) rise and normalization following a marathon. METHODS Nighty-eight participants (83 men, 15 women; 38.72 ± 3.63 years) were subjected to echocardiographic assessment and a cardiopulmonary exercise test (CPET) before the race. hs-TNT was measured before, immediately after and at 24, 48, 96, 144 and 192 h post-race. Speed and mean heart rate (HR) during the race were relativized to CPET values: peak speed (%VVMAX), peak HR (HR%MAX), speed and HR at the second ventilatory threshold (HR%VT2 and %VVT2). RESULTS Hs-TNT increased from pre- to post-race (5.74 ± 5.29 vs. 50.4 ± 57.04 ng/L; p < 0.001), seeing values above the Upper Reference Limit (URL) in 95% of the participants. At 24 h post-race, 39% of the runners still exceeded the URL (High hs-TNT group). hs-TNT rise was correlated with marathon speed %VVT2 (r = 0.22; p = 0.042), mean HR%VT2 (r = 0.30; p = 0.007), and mean HR%MAX (r = 0.32; p = 0.004). Moreover, the High hs-TNT group performed the marathon at a higher Speed %VVT2 (88.21 ± 6.53 vs. 83.49 ± 6.54%; p = 0.002) and Speed %VVMAX (72 ± 4.25 vs. 69.40 ± 5.53%; p = 0.009). hs-TNT showed no significant associations with cardiopulmonary fitness and echocardiographic measures, except for a slight correlation with left ventricular end systolic diameter (r = 0.26; p = 0.018). CONCLUSION Post-race hs-TNT was above the URL in barely all runners. Magnitude of hs-TNT rise was correlated with exercise mean HR; whereas, its normalization kept relationship with marathon relative speed.
Collapse
Affiliation(s)
- Ignacio Martínez-Navarro
- Physical Education and Sports Department, Faculty of Physical Activity and Sport Sciences, University of Valencia, C/Gascó Oliag 3, 46010, Valencia, Spain. .,Sports Health Unit, Vithas 9 de Octubre Hospital, Valencia, Spain.
| | - J Sánchez-Gómez
- Sports Health Unit, Vithas 9 de Octubre Hospital, Valencia, Spain.,Universitary Clinical Hospital of Valencia, Valencia, Spain
| | - D Sanmiguel
- Sports Health Unit, Vithas 9 de Octubre Hospital, Valencia, Spain.,General Hospital of Valencia, Valencia, Spain
| | - E Collado
- Faculty of Health Sciences, Jaume I University, Castellón de la Plana, Castellon, Spain
| | - B Hernando
- Department of Medicine, Jaume I University, Castellón de la Plana, Castellon, Spain
| | - N Panizo
- Faculty of Health Sciences, Jaume I University, Castellón de la Plana, Castellon, Spain.,Universitary Doctor Peset Hospital of Valencia, Valencia, Spain
| | - C Hernando
- Sport Service, Jaume I University, Castellón de la Plana, Castellon, Spain.,Department of Education and Specific Didactics, Jaume I University, Castellón de la Plana, Castellon, Spain
| |
Collapse
|
5
|
Adam-Artigues A, Tormo E, Rojo F, Perez-Fidalgo J, Zazo S, Gonzalez-Alonso P, Hernando C, Martínez M, Gambardella V, Poveda J, Simón S, Moragon S, Alonso E, Albanell J, Burgues O, Bermejo B, Eroles P, Lluch A, Cejalvo J, Rovira A. The role of AXL as mechanism of resistance to trastuzumab and a prognostic factor in breast cancer HER2 positive: A translational approach. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz242.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
6
|
Cejalvo J, Moragon S, Ortega B, Hernando C, Martínez M, Gambardella V, Tarazona Llavero N, Roda D, Burgues O, Alonso E, Simón S, Poveda J, Rentero P, Zuñiga S, Bermejo B, Lluch A, Cervantes A. Clinical application of mutational analysis in breast cancer patients: The relevance of PIK3CA analysis for precision medicine. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz242.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
7
|
Cortes J, Martin M, Pernas S, Gomez Pardo P, Lopez-Tarruella S, Gil-Martin M, Manso L, Ciruelos E, Perez-Fidalgo JA, Hernando C, Ademuyiwa FO, Weilbaecher K, Mayer I, Pluard TJ, Martinez Garcia M, Vahdat L, Wach A, Barker D, Romagnoli B, Kaufman PA. Abstract PD1-02: Withdrawn. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-pd1-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Citation Format: Cortes J, Martin M, Pernas S, Gomez Pardo P, Lopez-Tarruella S, Gil-Martin M, Manso L, Ciruelos E, Perez-Fidalgo JA, Hernando C, Ademuyiwa FO, Weilbaecher K, Mayer I, Pluard TJ, Martinez Garcia M, Vahdat L, Wach A, Barker D, Romagnoli B, Kaufman PA. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr PD1-02.
Collapse
Affiliation(s)
- J Cortes
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| | - M Martin
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| | - S Pernas
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| | - P Gomez Pardo
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| | - S Lopez-Tarruella
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| | - M Gil-Martin
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| | - L Manso
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| | - E Ciruelos
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| | - JA Perez-Fidalgo
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| | - C Hernando
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| | - FO Ademuyiwa
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| | - K Weilbaecher
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| | - I Mayer
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| | - TJ Pluard
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| | - M Martinez Garcia
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| | - L Vahdat
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| | - A Wach
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| | - D Barker
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| | - B Romagnoli
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| | - PA Kaufman
- Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institute of Oncology IOB, QuironGroup, Madrid and Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC Universidad Complutense, Madrid, Spain; Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Washington University, St. Louis, MO; Vanderbilt University School of Medicine, Nashville, TN; St Luke's Cancer Institute, Kansas City, MO; Hospital del Mar, Barcelona, Spain; Weill Cornell Medicine, New York, NY; Polyphor Ltd, Allschwil, Switzerland; Darmouth-Hitchcock Medical Center, Lebanon, NH
| |
Collapse
|
8
|
Kretschmar C, Peña-Oyarzun D, Hernando C, Hernández-Moya N, Molina-Berríos A, Hernández-Cáceres MP, Lavandero S, Budini M, Morselli E, Parra V, Troncoso R, Criollo A. Polycystin-2 Is Required for Starvation- and Rapamycin-Induced Atrophy in Myotubes. Front Endocrinol (Lausanne) 2019; 10:280. [PMID: 31133985 PMCID: PMC6517509 DOI: 10.3389/fendo.2019.00280] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/15/2018] [Accepted: 04/16/2019] [Indexed: 12/13/2022] Open
Abstract
Muscle atrophy involves a massive catabolism of intracellular components leading to a significant reduction in cellular and tissue volume. In this regard, autophagy, an intracellular mechanism that degrades proteins and organelles, has been implicated with muscle breakdown. Recently, it has shown that polycystin-2 (PC2), a membrane protein that belongs to the transient receptor potential (TRP) family, is required for the maintenance of cellular proteostasis, by regulating autophagy in several cell types. The role of PC2 in the control of atrophy and autophagy in skeletal muscle remains unknown. Here, we show that PC2 is required for the induction of atrophy in C2C12 myotubes caused by nutrient deprivation or rapamycin exposure. Consistently, overexpression of PC2 induces atrophy in C2C12 myotubes as indicated by decreasing of the myogenic proteins myogenin and caveolin-3. In addition, we show that inhibition of mTORC1, by starvation or rapamycin is inhibited in cells when PC2 is silenced. Importantly, even if PC2 regulates mTORC1, our results show that the regulation of atrophy by PC2 is independent of autophagy. This study provides novel evidence regarding the role of PC2 in skeletal muscle cell atrophy.
Collapse
Affiliation(s)
- Catalina Kretschmar
- Facultad de Odontología, Instituto de Investigación en Ciencias Odontológicas, Universidad de Chile, Santiago, Chile
- Facultad Ciencias Químicas y Farmacéuticas and Facultad Medicina, Advanced Center for Chronic Diseases, Universidad de Chile, Santiago, Chile
| | - Daniel Peña-Oyarzun
- Facultad de Odontología, Instituto de Investigación en Ciencias Odontológicas, Universidad de Chile, Santiago, Chile
- Facultad Ciencias Químicas y Farmacéuticas and Facultad Medicina, Advanced Center for Chronic Diseases, Universidad de Chile, Santiago, Chile
| | - Cecilia Hernando
- Facultad de Odontología, Instituto de Investigación en Ciencias Odontológicas, Universidad de Chile, Santiago, Chile
- Facultad Ciencias Químicas y Farmacéuticas and Facultad Medicina, Advanced Center for Chronic Diseases, Universidad de Chile, Santiago, Chile
| | - Nadia Hernández-Moya
- Facultad de Odontología, Instituto de Investigación en Ciencias Odontológicas, Universidad de Chile, Santiago, Chile
- Facultad Ciencias Químicas y Farmacéuticas and Facultad Medicina, Advanced Center for Chronic Diseases, Universidad de Chile, Santiago, Chile
| | - Alfredo Molina-Berríos
- Facultad de Odontología, Instituto de Investigación en Ciencias Odontológicas, Universidad de Chile, Santiago, Chile
| | - María Paz Hernández-Cáceres
- Departamento de Fisiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Sergio Lavandero
- Facultad Ciencias Químicas y Farmacéuticas and Facultad Medicina, Advanced Center for Chronic Diseases, Universidad de Chile, Santiago, Chile
- Facultad de Medicina, Centro de Estudios en Ejercicio, Metabolismo y Cáncer, Universidad de Chile, Santiago, Chile
- Cardiology Division, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, United States
| | - Mauricio Budini
- Facultad de Odontología, Instituto de Investigación en Ciencias Odontológicas, Universidad de Chile, Santiago, Chile
- Autophagy Research Center, Santiago, Chile
| | - Eugenia Morselli
- Departamento de Fisiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
- Autophagy Research Center, Santiago, Chile
| | - Valentina Parra
- Facultad Ciencias Químicas y Farmacéuticas and Facultad Medicina, Advanced Center for Chronic Diseases, Universidad de Chile, Santiago, Chile
- Facultad de Medicina, Centro de Estudios en Ejercicio, Metabolismo y Cáncer, Universidad de Chile, Santiago, Chile
- Autophagy Research Center, Santiago, Chile
| | - Rodrigo Troncoso
- Facultad Ciencias Químicas y Farmacéuticas and Facultad Medicina, Advanced Center for Chronic Diseases, Universidad de Chile, Santiago, Chile
- Autophagy Research Center, Santiago, Chile
- Laboratorio de Investigación en Nutrición y Actividad Física, Instituto de Nutrición y Tecnología de los Alimentos, Universidad de Chile, Santiago, Chile
- *Correspondence: Rodrigo Troncoso
| | - Alfredo Criollo
- Facultad de Odontología, Instituto de Investigación en Ciencias Odontológicas, Universidad de Chile, Santiago, Chile
- Facultad Ciencias Químicas y Farmacéuticas and Facultad Medicina, Advanced Center for Chronic Diseases, Universidad de Chile, Santiago, Chile
- Autophagy Research Center, Santiago, Chile
- Alfredo Criollo
| |
Collapse
|
9
|
Cortes Castan J, Martín M, Pernas Simon S, Gomez Pardo P, Lopez-Tarruella S, Gil Martin M, Manso L, Ciruelos E, Perez Fidalgo J, Hernando C, Ademuyiwa F, Weilbaecher K, Mayer I, Pluard T, Martinez Garcia M, Vahdat L, Wach A, Barker D, Romagnoli B, Kaufman P. Balixafortide (a novel CXCR4 inhibitor) and eribulin in HER2-neg metastatic breast cancer (MBC) patients (pts): A phase I trial. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy272.277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
10
|
Gonzalez Barrallo I, Perez Fidalgo J, Ramirez J, Burgues O, Sorlí J, Portoles O, Hernando C, Salas D, Lluch A. No effect of length time bias on the genomic risk in ER+ HER2-stage I-IIA breast cancer (BC) patients according to diagnosis in a screening programme: An exploratory analysis. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy297.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
11
|
Espinosa J, Madrigal J, De La Cruz AC, Guijarro M, Jimenez E, Hernando C. Short-term effects of prescribed burning on litterfall biomass in mixed stands of Pinus nigra and Pinus pinaster and pure stands of Pinus nigra in the Cuenca Mountains (Central-Eastern Spain). Sci Total Environ 2018; 618:941-951. [PMID: 29146076 DOI: 10.1016/j.scitotenv.2017.08.291] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/31/2017] [Revised: 08/01/2017] [Accepted: 08/29/2017] [Indexed: 06/07/2023]
Abstract
Fire severity, defined as the magnitude of fire effects in an ecosystem, is a key factor to consider in planning management strategies for protecting forests against fire. Although prescribed burning has been used as a fuel reduction tool in forest ecosystems, it is quite limited in the Mediterranean region. Furthermore, little is known about how tree crowns are affected by prescribed underburning aimed at reducing fire severity in conifer stands. As part of an ongoing study to assess the effects of prescribed burning on the tree canopy, litterfall is currently being monitored in a network of experimental plots located in mixed (Pinus nigra and Pinus pinaster) and pure (P. nigra) conifer stands in the Cuenca Mountains (Castilla La Mancha, Spain). A total of 12 study plots (30m×30m) were established in a completely randomized experimental design to determine the effect of burning, with 2 treatments: no burning (control) and burning (i.e. with three replicate plots for each treatment and site). Burning was conducted in May 2016. In each plot, 8 litterfall collectors were installed at regular intervals, according to international protocols (ICP Forests), and all biomass falling into the collectors is being monitored monthly. The specific objective of this study is to assess how prescribed burning affects the rate of generation of foliar and non-foliar litterfall biomass due to the fire. In addition, the Leaf Area Index was estimated before burning and one year later to verify possible changes in the structure of the stands. This information could be used to help minimize the negative impacts of prescribed underburning on litterfall. To our knowledge, this study represents the first attempt to evaluate the effect of prescribed burning on litterfall biomass in Europe.
Collapse
Affiliation(s)
- J Espinosa
- INIA, Forest Research Centre, Department of Silviculture and Forest Management, Forest Fire Laboratory, Ctra. Coruña Km 7.5, 28040 Madrid, Spain.
| | - J Madrigal
- INIA, Forest Research Centre, Department of Silviculture and Forest Management, Forest Fire Laboratory, Ctra. Coruña Km 7.5, 28040 Madrid, Spain; iuFOR, University Institute for Sustainable Forest Management, uVA-INIA, Spain
| | - A C De La Cruz
- INIA, Forest Research Centre, Department of Silviculture and Forest Management, Forest Fire Laboratory, Ctra. Coruña Km 7.5, 28040 Madrid, Spain
| | - M Guijarro
- INIA, Forest Research Centre, Department of Silviculture and Forest Management, Forest Fire Laboratory, Ctra. Coruña Km 7.5, 28040 Madrid, Spain; iuFOR, University Institute for Sustainable Forest Management, uVA-INIA, Spain
| | - E Jimenez
- Forest Research Center of Lourizán. Xunta de Galicia, 36080 Pontevedra, Spain
| | - C Hernando
- INIA, Forest Research Centre, Department of Silviculture and Forest Management, Forest Fire Laboratory, Ctra. Coruña Km 7.5, 28040 Madrid, Spain; iuFOR, University Institute for Sustainable Forest Management, uVA-INIA, Spain
| |
Collapse
|
12
|
Peña-Oyarzun D, Troncoso R, Kretschmar C, Hernando C, Budini M, Morselli E, Lavandero S, Criollo A. Hyperosmotic stress stimulates autophagy via polycystin-2. Oncotarget 2017; 8:55984-55997. [PMID: 28915568 PMCID: PMC5593539 DOI: 10.18632/oncotarget.18995] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2017] [Accepted: 06/21/2017] [Indexed: 12/13/2022] Open
Abstract
Various intracellular mechanisms are activated in response to stress, leading to adaptation or death. Autophagy, an intracellular process that promotes lysosomal degradation of proteins, is an adaptive response to several types of stress. Osmotic stress occurs under both physiological and pathological conditions, provoking mechanical stress and activating various osmoadaptive mechanisms. Polycystin-2 (PC2), a membrane protein of the polycystin family, is a mechanical sensor capable of activating the cell signaling pathways required for cell adaptation and survival. Here we show that hyperosmotic stress provoked by treatment with hyperosmolar concentrations of sorbitol or mannitol induces autophagy in HeLa and HCT116 cell lines. In addition, we show that mTOR and AMPK, two stress sensor proteins involved modulating autophagy, are downregulated and upregulated, respectively, when cells are subjected to hyperosmotic stress. Finally, our findings show that PC2 is required to promote hyperosmotic stress-induced autophagy. Downregulation of PC2 prevents inhibition of hyperosmotic stress-induced mTOR pathway activation. In conclusion, our data provide new insight into the role of PC2 as a mechanosensor that modulates autophagy under hyperosmotic stress conditions.
Collapse
Affiliation(s)
- Daniel Peña-Oyarzun
- Advanced Center for Chronic Diseases, Facultad Ciencias Quimicas y Farmaceuticas & Facultad Medicina, Universidad de Chile, Santiago, Chile.,Center for Molecular Studies of the Cell, Facultad de Medicina, Universidad de Chile, Santiago, Chile
| | - Rodrigo Troncoso
- Advanced Center for Chronic Diseases, Facultad Ciencias Quimicas y Farmaceuticas & Facultad Medicina, Universidad de Chile, Santiago, Chile.,Instituto de Nutrición y Tecnología de los Alimentos, Universidad de Chile, Santiago, Chile
| | - Catalina Kretschmar
- Advanced Center for Chronic Diseases, Facultad Ciencias Quimicas y Farmaceuticas & Facultad Medicina, Universidad de Chile, Santiago, Chile.,Instituto de Investigación en Ciencias Odontológicas, Facultad de Odontología, Universidad de Chile, Santiago, Chile
| | - Cecilia Hernando
- Advanced Center for Chronic Diseases, Facultad Ciencias Quimicas y Farmaceuticas & Facultad Medicina, Universidad de Chile, Santiago, Chile.,Instituto de Investigación en Ciencias Odontológicas, Facultad de Odontología, Universidad de Chile, Santiago, Chile
| | - Mauricio Budini
- Instituto de Investigación en Ciencias Odontológicas, Facultad de Odontología, Universidad de Chile, Santiago, Chile
| | - Eugenia Morselli
- Departamento de Fisiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Sergio Lavandero
- Advanced Center for Chronic Diseases, Facultad Ciencias Quimicas y Farmaceuticas & Facultad Medicina, Universidad de Chile, Santiago, Chile.,Center for Molecular Studies of the Cell, Facultad de Medicina, Universidad de Chile, Santiago, Chile.,Department of Internal Medicine (Cardiology Division), University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - Alfredo Criollo
- Advanced Center for Chronic Diseases, Facultad Ciencias Quimicas y Farmaceuticas & Facultad Medicina, Universidad de Chile, Santiago, Chile.,Instituto de Investigación en Ciencias Odontológicas, Facultad de Odontología, Universidad de Chile, Santiago, Chile
| |
Collapse
|
13
|
Ferrer L, Gaillardin F, Cayuela A, Felt E, Hernando C, Collazos F, Ronda E, Casabona J. Children health determinants in a multi-site cohort of immigrant families in Spain (PELFI Study). Eur J Public Health 2016. [DOI: 10.1093/eurpub/ckw175.114] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
14
|
Fidalgo JP, Caballero A, Cejalvo J, Burgues O, Hernando C, Tolosa P, Iranzo A, Bermejo B, Sabio JR, Magro A, Lluch-Hernandez A. Long lasting survival (LLS) after removal of primary tumor (PT) in metastatic breast cancer (MBC). Impact of age on outcome. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw365.31] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
15
|
Della Rocca G, Hernando C, Madrigal J, Danti R, Moya J, Guijarro M, Pecchioli A, Moya B. Possible land management uses of common cypress to reduce wildfire initiation risk: a laboratory study. J Environ Manage 2015; 159:68-77. [PMID: 26046989 DOI: 10.1016/j.jenvman.2015.05.020] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/21/2014] [Revised: 03/20/2015] [Accepted: 05/16/2015] [Indexed: 05/23/2023]
Abstract
Accurate determination of flammability is required in order to improve knowledge about vegetation fire risk. Study of the flammability of different plant species is essential for the Mediterranean area, where most ecosystems are adapted to natural fire but vulnerable to recurrent human-induced fires, which are the main cause of forest degradation. However, the methods used to evaluate vegetation flammability have not yet been standardized. Cupressus sempervirens is a native or naturalized forest tree species in the Mediterranean area that is able to tolerate prolonged drought and high temperatures. The aim of this study was to characterize the flammability of C. sempervirens var. horizontalis at particle level by using different bench-scale calorimetry techniques (mass loss calorimeter, epiradiator and oxygen bomb) to determine the main flammability descriptors (ignitability, sustainability, combustibility and consumability) in live crown and litter samples. Our findings indicate that this variety of cypress is relatively resistant to ignition because of the high ash content, the high critical heat flux, the high time to ignition displayed by both crown and litter samples and the ability of the leaves to maintain a high water content during the summer. We also discuss the possibility of exploiting some morphological, functional and ecological traits of the species to construct a barrier system (with selected varieties of cypress) as a promising complementary land management tool to reduce the fire spread and intensity in a Mediterranean context.
Collapse
Affiliation(s)
- G Della Rocca
- Institute for Sustainable Plant Protection, IPSP-CNR, Via Madonna del Piano 10, I-50019, Sesto Fiorentino, FI, Italy.
| | - C Hernando
- INIA - CIFOR, Department of Silviculture and Forest Management, Crta. A Coruña Km 7.5, 28040, Madrid, Spain; Sustainable Forest Management Institute, UVa-INIA, Spain.
| | - J Madrigal
- INIA - CIFOR, Department of Silviculture and Forest Management, Crta. A Coruña Km 7.5, 28040, Madrid, Spain; Sustainable Forest Management Institute, UVa-INIA, Spain.
| | - R Danti
- Institute for Sustainable Plant Protection, IPSP-CNR, Via Madonna del Piano 10, I-50019, Sesto Fiorentino, FI, Italy.
| | - J Moya
- Monumental Trees Department, Imelsa - Valencia Provincial Council, C/ Conde Trenor 9, 46003, Valencia, Spain.
| | - M Guijarro
- INIA - CIFOR, Department of Silviculture and Forest Management, Crta. A Coruña Km 7.5, 28040, Madrid, Spain; Sustainable Forest Management Institute, UVa-INIA, Spain.
| | - A Pecchioli
- Institute for Sustainable Plant Protection, IPSP-CNR, Via Madonna del Piano 10, I-50019, Sesto Fiorentino, FI, Italy.
| | - B Moya
- Monumental Trees Department, Imelsa - Valencia Provincial Council, C/ Conde Trenor 9, 46003, Valencia, Spain
| |
Collapse
|
16
|
Gallach S, Calabuig-Fariñas S, Jantus-Lewintre E, Montaner D, Escorihuela E, Castellano J, Figueroa S, Blasco A, Hernando C, Guijarro R, Camps C. 545 MiRNAs related to KRAS mutational status in resectable non-small cell lung cancer. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)70671-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
17
|
Hernando C. 1.245 HEMICHOREA-HEMIBALLISM: NON KETOTIC HYPERGLYCEMIA SYMPTOM. Parkinsonism Relat Disord 2012. [DOI: 10.1016/s1353-8020(11)70303-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
18
|
Sanmartin E, Gallach S, Sirera R, Hernando C, Honguero A, Guijarro R, Martorell M, Camps C, Jantus-Lewintre E. Prognostic implications of lymphangiogenic markers in early-stage NSCLC. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e21108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
19
|
Madrigal J, Hernando C, Guijarro M, Díez C, Jiménez E. Biomass accumulation and carbon sequestration after heavy mechanical thinning on post-fire Pinus pinaster seedlings (Monte ‘Fraguas’, Guadalajara, Central Spain). ACTA ACUST UNITED AC 2006. [DOI: 10.5424/srf/2006152-00967] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
20
|
Madrigal J, Hernando C, Martinez E, Guijarro M, Diez C. Post-fire regeneration of P. pinaster Ait. in Sierra de Guadarrama (Central Spain): modelling of initial density and survival. ACTA ACUST UNITED AC 2005. [DOI: 10.5424/srf/2005141-00872] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
21
|
Hernando C, Carrera M, Ribas I, Parear N, Baraibar R, Egocue J, Fuster C. Prenatal and postnatal characterization of Y chromosome structural anomalies by molecular cytogenetic analysis. Prenat Diagn 2002; 22:802-5. [PMID: 12224075 DOI: 10.1002/pd.415] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
We describe three cases in which we used fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR) and comparative genomic hybridization (CGH) to characterize Y chromosome structural anomalies, unidentifiable by conventional G-banding. Case 1 was a 46,X,+mar karyotype; FISH analysis revealed an entire marker chromosome highlighted after hybridization with the Y chromosome painting probe. The PCR study showed the presence of Y chromosome markers AMG and SY620 and the absence of SY143, SY254 and SY147. CGH results confirmed the loss of Yq11.2-qter. These results indicated the presence of a deletion: del(Y)(q11.2). Case 2 was a 45,X [14]/46,XY[86] karyotype with a very small Y chromosome. The PCR study showed the presence of Y chromosome markers SY620 and AMG, and the absence of SY143, SY254 and SY147. CGH results showed gain of Yq11.2-pter and loss of Yq11.2-q12. These results show the presence of a Yp isodicentric: idic(Y)(q11.2). Case 3 was a 45,X,inv(9)(p11q12)[30]/46,X,idic(Y)(p11.3?),inv(9)(p11q12)[70] karyotype. The FISH signal covered all the abnormal Y chromosome using a Y chromosome paint. The PCR study showed the presence of Y chromosome markers AMG, SY620, SY143, SY254 and SY147. CGH only showed gain of Yq11.2-qter. These results support the presence of an unbalanced (Y;Y) translocation. Our results show that the combined use of molecular and classical cytogenetic methods in clinical diagnosis may allow a better delineation of the chromosome regions implicated in specific clinical disorders.
Collapse
Affiliation(s)
- C Hernando
- Unitat de Biologia, Facultat de Medicina, Universitat Autònoma de Barcelona, E-08193 Bellaterra, Barcelona, Spain
| | | | | | | | | | | | | |
Collapse
|
22
|
Hernando C, Plaja A, Rigola MA, Pérez MM, Vendrell T, Egocue J, Fuster C. Comparative genomic hybridisation shows a partial de novo deletion 16p11.2 in a neonate with multiple congenital malformations. J Med Genet 2002; 39:E24. [PMID: 12011165 PMCID: PMC1735111 DOI: 10.1136/jmg.39.5.e24] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
23
|
Cubells JM, de Blas A, Hernando C, Rodríguez del Barrio E. [Bovine cerebral cortex gangliosides in the treatment of radicular lesions (author's transl)]. Med Clin (Barc) 1980; 75:156-60. [PMID: 7412438] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Bovine cerebral cortex gangliosides were given to 71 patients following surgical intervention for radicular compression of different etiologies. The extract was given for 20-25 days at daily doses of 20 mg for the first 15 days and 10 mg thereafter until completion of treatment. H reflexology was shown to be a good method for evaluating the response to therapy. Most information was gained by the use of the following parameters: AM/AH, AH/IE, and AH/number of stimulation pulses. The results have been compared with those obtained prior to surgical therapy, those collected in a series of 68 normal individuals and, finally, with those found in another series of 71 patients that were treated postoperatively with conventional measures (B vitamins, analgesics, antiinflammatory drugs, corticoids, etc.). The statistical analysis of the final data shows that the reflexologic parameters tested revert to normal quicker in the patients treated with gangliosides than in those not receiving such therapy. The authors consider the use of gangliosides of great interest in the postoperative period after surgical relief of radicular compression.
Collapse
|
24
|
Hernando C, De Blas A, Cubells JM. [Cytidine diphosphate cholinne -- a new drug in the treatment of spasticity]. Rev Clin Esp 1978; 151:313-7. [PMID: 741011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
25
|
Villarejo FJ, Hernando C, Roda E. [Aneurysms of distal anterior cerebral artery (author's transl)]. Rev Esp Otoneurooftalmol Neurocir 1975; 33:229-36. [PMID: 1230931] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|
26
|
|
27
|
Odoriz B, Hernando C, Dierssen G. [Various observations on cerebral atrophy due to small subcortical injuries]. Rev Clin Esp 1969; 112:261-74. [PMID: 5345179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|
28
|
Dierssen G, Hernando C, Odoriz B. [Effects of stimulation of the posterior cingular region in man]. Rev Clin Esp 1969; 112:15-26. [PMID: 5766955] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
|
29
|
Dierssen G, Hernando C, Odoriz B. [Influence of subcortical stimulation on the tremor and rigidity of Parkinson's disease]. Rev Clin Esp 1968; 111:513-8. [PMID: 4894970] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
30
|
Dierssen G, Hernando C, Odoriz B. [Observations on the influence of the pyramidal lesion in Parkinson's homolateral tumor]. Rev Clin Esp 1968; 111:63-6. [PMID: 5742417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
|
31
|
Sánchez Moreno G, Dierssen G, Hernando C. [Study of sensorial representations of the median supracallous cortex in the cat using evoked potentials. 2. Tongue. Hypoglossal nerve and the lingual propioceptive sensitivity]. Rev Clin Esp 1966; 102:270-4. [PMID: 5993266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
|